Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails
- 4 December 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 62 (4), 727-736
- https://doi.org/10.1007/s00262-012-1378-2
Abstract
The genetic modification of CD8+ T cells using anti-tumor T-cell receptors (TCR) or chimeric antigen receptors is a promising approach for the adoptive cell therapy of patients with cancer. We previously developed a simplified method for the clinical-scale generation of central memory-like (Tcm) CD8+ T cells following transduction with lentivirus encoding anti-tumor TCR and culture in the presence of IL-2. In this study, we compared different cytokines or combinations of IL-2, IL-7, IL-12, IL-15, and IL-21 to expand genetically engineered CD8+ T cells. We demonstrated that specific cytokine combinations IL-12 plus IL-7 or IL-21 for 3 days followed by withdrawal of IL-12 yielded the phenotype of CD62LhighCD28high CD127highCD27highCCR7high, which is associated with less-differentiated T cells. Genes associated with stem cells (SOX2, NANOG, OCT4, and LIN28A), were also up-regulated by this cytokine cocktail. Moreover, the use of IL-12 plus IL-7 or IL-21 yielded CD8 T cells showing enhanced persistence in the NOD/SCID/γc−/− mouse model. This defined cytokine combination could also alter highly differentiated TIL from melanoma patients into cells with a less-differentiated phenotype. The methodology that we developed for generating a less-differentiated anti-tumor CD8+ T cells ex vivo may be ideal for the adoptive immunotherapy of cancer.Keywords
This publication has 42 references indexed in Scilit:
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2011
- Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor EnvironmentMolecular Therapy, 2011
- In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cellsCancer Immunology, Immunotherapy, 2011
- Reprogramming of T Cells from Human Peripheral BloodCell Stem Cell, 2010
- Reprogramming of Human Peripheral Blood Cells to Induced Pluripotent Stem CellsCell Stem Cell, 2010
- A Distinct Subset of Self-Renewing Human Memory CD8+ T Cells Survives Cytotoxic ChemotherapyImmunity, 2009
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cellsNature Medicine, 2009
- Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognitionGene Therapy, 2008
- Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine modelCancer Immunology, Immunotherapy, 2007